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Novel diagnostic tests are usually compared with gold standard tests for evaluating diagnostic accuracy.
For assessing antimicrobial resistance (AMR) to bovine respiratory disease (BRD) pathogens, phenotypic
broth microdilution method is used as gold standard (GS). The objective of the thesis is to evaluate the
optimal cycle threshold (Ct) generated by real-time polymerase chain reaction (rtPCR) to genes that confer
resistance that will translate to the phenotypic classification of AMR. Data from two different
methodologies are assessed to identify Ct that will discriminate between resistance (R) and susceptibility
(S). First, the receiver operating characteristic (ROC) curve was used to determine the optimal Ct by
optimizing the area under the curve (AUC), which was further validated by assessing the sufficiency of
sample sizes involved in this study and by 5-fold cross-validation. AUC is a straightforward method, using
a default probability threshold (Pt) of 0.5 and independent of misclassification cost to discriminate
between the classes. An alternative methodology - H measure - is proposed, which selects the Pt based
on minimum error rate. The H measure is quite flexible, and the threshold can be selected according to
researchers’ interest by minimizing the false positive or negative rate.
A total of 297 lung and 111 nasal swabs from bovine were tested for AMR using the gold standard
and rtPCR for three specific drugs. The level of agreement between the two tests were measured using
Cohen’s Kappa ( ). Using the first approach, the optimal Ct for lung tissue samples was between 32.6 and
35.7, with a good level of agreement between the two tests. For the nasal tissue, the rtPCR results were
only validated for one drug with a Ct of 33.3 with a moderate level of agreement. For the second approach,

the lungs and nasal tissues are combined, and the optimal Ct is evaluated by taking the average from AUC
and H measure and lies between 32.0 and 32.9 with a moderate level of agreement.
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1. Chapter 1 - Introduction
1.1

Diagnostic test

Diagnostic tests are a common way to empower and enable physicians, veterinarians, laboratory
technologists, or researchers to decide whether a disease or suspected condition is present or not. The
outcome of the diagnostic tests can either be continuous or categorical, but they are usually classified as
positive or negative. For a perfect diagnostic test, a positive result implies the presence of the presumed
condition, and a negative result means the absence of the same condition. In reality, the diagnostic tests
are always associated with some uncertainty, and a positive test would neither imply the presence of the
condition nor a negative test suggesting the absence of the condition.
Statistically, sensitivity (

) and specificity (

accuracy of any diagnostic tests [1-4].

) are two essential properties to evaluate the

is defined as the true positive rate or the probability that the

diagnostic test is positive given the presumed disease, or suspected condition is present, and

is defined

as the true negative rate or the probability that the diagnostic test is negative given the suspected
condition is absent. The evaluation of a diagnostic test is usually represented and calculated using the 2x2
contingency table, as shown in Table 1.1.
and

are calculated in equation 1.1 and 1.2 using Table 1.1 as shown below,
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There are additional measures that are useful in evaluating the accuracy of a diagnostic test, namely,
positive predictive value (

) and negative predictive value (

).

test is positive, the presence of the disease is correctly diagnosed and

is the probability that given the
is the probability that given

the test is negative, the absence of the disease is correctly diagnosed. It is important to note that both

2
measures rely on the prevalence of the disease or condition itself, which is usually determined using gold
standard results.
|
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1.4

In an ideal world, a diagnostic test should discriminate between diseased and non-diseased subjects
perfectly, i.e.,

=

= 0, but that is rarely true. So, to evaluate the accuracy of a diagnostic test, the

objective is to minimize the misclassification, or

and

. In general, diagnostic tests are used for two

purposes, rule-out test, and rule-in test. For the rule-out test,

[5-7] and

[5, 7, 8] need to be higher

for ensuring that a test is negative only when the condition or disease of interest is absent. For rule-in test
[5-7] and

[5, 7, 8] need to be higher for ensuring that a test is positive only when the condition

or disease of interest is present.

1.2

Comparison of two diagnostic tests – gold standard vs. novel test

As technologies are getting more advanced, multiple diagnostic tests and improved methods are
emerging, which are either more efficient, cost-effective, or useful than the existing ones for any specific
disease or condition. The primary objective of the tests continues to be the same, i.e., to diagnose the
disease or condition, but the principle mechanism or modality behind the tests might be completely
different. In many cases different phenotypic or genotypic biomarkers can also be used for the diagnostics,
resulting in a completely different mode of the outcome. One of the conventional methods to evaluate
multiple tests is by comparing the accuracy between the tests since their mechanisms and outcome are
different from each other.
Generally, for most diseases, among all available diagnostic tests, there are usually few tests
which are widely recognized and acknowledged as a reliable test based on certain conditions and are
termed as “gold standard.” Gold standard is commonly referred to as a benchmark and is considered the
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best available for discriminating between diseased and non-diseased subjects [9-11]. For many conditions
or diseases, the acknowledged gold standard tests can be invasive, expensive, not widely accessible, or
time-consuming. In many cases the gold standard tests can only be applicable to post-mortem analysis
which is not ideal for treatment. This leads to the development of novel diagnostic tests, which aims to
address all the shortcomings of the existing tests and hence the need for determining an equivalent
accuracy like the gold standard method.
Assuming the gold standard result can be categorized into either positive or negative classification
or any other classifications as per the requirement, the goal is to determine the novel diagnostic test
having similar accuracy as the gold standard. There can be two possibilities; first, the results for the novel
test are also categorical like the gold standard method, and second, the results are continuous in nature.
For the first case, a similar contingency table can be created to compare the two tests and calculate
different measures of interest. Table 1.2 shows the 2x2 representation of the results of the gold standard

and the novel diagnostic test on the same subjects. Using equation 1.1 - 1.4 and Table 1.2,
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The novel test is considered accurate if
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are high enough.

For the second case, where the novel test results are continuous in nature, it is not feasible to
calculate

and

directly as described in Table 1.2. Instead, the cutoff point needs to be determined

on the continuous scale that would discriminate between the positive and the negative results. Figure 1.1
represents the two scenarios. First, we have an ideal scenario where the cutoff point can distinguish
between diseased and non-diseased subjects assuming there is no misclassification. Second, we have a
non-ideal scenario where the cutoff point is unable to discriminate between the two groups leading to
the possibility of misclassification.
As ideal scenarios are rarely true, there will always be some misclassification in the form of either diseased
subjects being classified as non-diseased, i.e., false negative or non-diseased subjects categorized as
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diseased, i.e., false positive. A conventional methodology used to determine the cutoff is by using a
Receiver Operating Characteristics (ROC) curve [9, 12-14]. The ROC is a graphical representation of
true positive rate versus 1 −

or

or false positive rate to determine the preferred cutoff over a series of

the possible cutoffs. The optimal cutoff that translates the continuous value into a binary classification is
determined by optimizing the area under the curve (AUC) [15]. Figure 1.2 shows a sample ROC curve along
with the AUC. The AUC usually takes values between 0.5 and 1; an AUC value closer to 1 helps in
discriminating between the gold standard and the novel diagnostic test by minimizing the misclassification
error. Once that cutoff is determined, the observations can be aligned as per Table 1.2, the required
measures can then be calculated, and consequently, decisions can be taken regarding the accuracy of the
diagnostic test. This process can be repeated until the desired accuracy is achieved.

1.3

Disease of interest and relevant diagnostic tests

For this study, our disease of interest is the bovine respiratory disease (BRD), which can be caused by
antimicrobial-resistant bacterial pathogens. BRD is a common respiratory disease complex affecting
cattle, usually in the respiratory tract. It can be caused due to multiple factors ranging from viral infections,
bacterial infections, and environmental factors, with potential contributions from all of these factors [16,
17]. The economic impact due to BRD on the feedlot industry is multifold as it includes not only the cost
for treatment but also the additional costs due to loss of productivity and performance resulting from
mortality and morbidity associated with it. The major clinical signs of BRD are pneumonia, along with
other conditions like fever, depression, and decreased appetite [18, 19]. Bacterial pathogens are
commonly one of the primary contributors to the BRD. Multiple bacterial pathogens are frequently
involved in the disease, which may lead to the treatment which is usually comprised of more than one
antimicrobial drug [20, 21]. Use of multiple antimicrobial drugs and treatments often leads to
antimicrobial resistance rendering the existing treatment ineffective, and exaggerating the negative
economic impact.
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As explained by the World Health Organization (WHO), antimicrobial resistance (AMR) occurs
when microorganisms like viruses, bacteria, fungi, or other parasites make ineffective the existing
treatments used for curing the infections or conditions caused by them [22]. AMR has increasingly become
a global public health concern, as it can spread between humans and animals [22]. So, there is an
imperative need to detect AMR as early as possible and commence treatment appropriately. Detection of
AMR in cattle suffering from BRD will help the animals and feedlot industry in reducing the treatment cost
by ensuring the most effective therapy is selected. It will also help in addressing the public health concern,
as the resistance can potentially be transferred from BRD pathogens to zoonotic bacteria that can affect
humans through mobile genetic elements associated with AMR.
There are several methods of AMR detection to identify if the sample tested has shown any
resistance to certain antimicrobials, which would enable the veterinarian to make informed decisions
regarding BRD treatment. In general, the methods can be categorized into phenotypic and genotypic tests
although all have the same objective, each having advantages and disadvantages.
Phenotypic tests are typically used for testing antimicrobial resistance or susceptibility. Some of the
standard phenotypic tests are [4, 23, 24]:
•

Broth dilution method

•

Disk – diffusion method

•

Epsilometer testing (Etest)

•

Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS)

•

Automated systems/methods

Broth dilution method [24] and disk – diffusion [23] method are the most widely used methods for testing
AMR and have a well-standardized index provided by Clinical and Laboratory Standards Institute (CLSI)
[23, 24]; hence they are referred to as ‘gold standard.’ For this study, we will consider the broth dilution
as a gold standard, as it is ideal in that it provides a quantitative objective assessment of in vitro
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susceptibility. Broth dilution is a culture-based method where bacteria are grown in a liquid medium
containing dilutions of the antimicrobial drugs and left overnight for incubation. Antimicrobial resistance
is then determined by the appearance of visible growth based on broth turbidity, and the minimum
inhibitory concentration (MIC) is identified as the lowest concentration of the antimicrobial agent that
prevents the visible growth of the bacterium. Based on the MIC results, resistance or susceptibility can be
determined by comparing the MIC index with a well-established breakpoint based on the consideration
of pharmacokinetics and clinical consequences as per the guidelines of the CLSI. One potential drawback
for this method is that it is time and labor consuming, as it involves the isolation and identification of the
bacterial pathogen in pure culture then followed by long incubation time. Due to the long incubation time,
studies have shown that there is a possibility of an increase in false positives [23, 25] and chances of
contamination [23], which also adds on as drawbacks for the gold standard method. The method is also
technically challenging and requires significant quality control and attention to detail to ensure accurate
results.
Genotypic or molecular tests are now increasingly being used for AMR testing since they are
culture-independent, which do not require isolation of the bacterial pathogens or long incubation time.
Some of the common molecular tests are [4, 23, 26]:•

Polymerase chain reaction (PCR)

•

DNA hybridization

For this study, a variation of PCR called multiplex real-time PCR, or quantitative PCR (qPCR) is used as the
novel diagnostic test to detect AMR. PCR is an efficient molecular technique that studies the amplification
of the target resistant genes and provides rapid and reliable results. The outcome of a real-time PCR assay
is provided by the cycle threshold (Ct), which is defined as the number of cycles required for the
fluorescent signal to cross the threshold. A higher value of Ct indicates a lower level of target genes
present in the tested sample, while a lower Ct value refers to a higher quantity present in the sample.
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Figure 1.3 is a schematic illustration of output or results obtained from the AMR testing using both broth
dilution and multiplex real-time PCR.
Unlike the gold standard method where AMR outcome is determined by the MIC method, one of the
most significant disadvantages of using genetic methods like PCR is that there is no standard benchmark
available to categorize the outcome or results. The objective of this study is to develop a statistical
methodology that would help establish a benchmark of the results obtained from the PCR method having
an equivalent accuracy to the existing gold standard method rather than to compare the superiority
between them. This thesis has three more chapters. In Chapter 2, the use of the conventional ROC
approach as mentioned in Section 1.2 to determine the optimal benchmark for real-time PCR is
established. In Chapter 3, an alternative methodology using H-measure is used to determine the optimal
benchmark. In Chapter 4, the two methodologies are compared, along with a discussion of the
appropriate applicable conditions for each method.
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2. Chapter 2 – Application of the conventional methodology
2.1

Introduction

Bovine respiratory disease (BRD) is one of the most common and costly diseases affecting the cattle and
beef industry. Studies show that a total of 97% of feedlots, or 16% of the cattle in the United States, are
affected by BRD, resulting in an economic loss estimated more than $4 billion to the beef industry in the
United States[27]. BRD is attributed to a complex interaction between multiple factors such as
environment, viruses, bacteria, and the hosts [16]. The onset of the disease is commonly caused by viral
infections, which may be responsible for altering the host defense mechanisms, allowing opportunistic
bacterial pathogens to replicate and colonize deeper in the lung, causing cellular death and dysfunction
which leads to BRD. Additionally, environmental factors such as crowding, poor ventilation, weather, and
weaning increase the stress among the animals and subsequent compromised immunity [28]. The severity
of BRD often increases due to the coexistence of multiple viral and bacterial pathogens leading to higher
mortality and morbidity rates and associated economic burdens [29, 30].
Among the pathogenic bacteria causing BRD in feedlot cattle and neonatal calves, Mannheimia
haemolytica is the most frequently isolated, followed by Histophilus somni, and Pasteurella multocida
[20]. The multifactorial nature of BRD often complicates the disease management challenging, and
typically consisting of the administration of antimicrobial drugs for treatment and/or metaphylaxis control
purposes. These may potentially select for multidrug resistance among those bacterial pathogens [31].
Recent studies have shown that the resistance in BRD bacterial pathogens has become increasingly
frequent, in particular resistance to approved drugs such as macrolides and tetracyclines [21], the most
commonly used antibiotics on beef cattle feedlots in the United States [32-35]. The development of
antimicrobial resistance compromises the effectiveness of antibiotic treatment and control of BRD, which
may lead to a higher mortality rate and lower productivity among cattle population. Besides, the
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increasing antimicrobial resistance in BRD pathogens may pose a great threat to public health, as resistant
genes found in BRD pathogens are contained on and could potentially be transferred through integrative
conjugative elements (ICE) from BRD pathogens to zoonotic bacteria [33]. Hence, rapid and accurate
detection of antibiotic resistant BRD pathogens, especially those exhibiting multidrug resistance, is an
urgent need for monitoring the current situation. Also, evaluating the efficacy of the potential
intervention in reducing antimicrobial resistance will ultimately benefit the beef industry and protect
animal and human health by enabling optimal selection of drugs for BRD therapy.
Classically, antimicrobial resistance is determined by culture-based methods, which commonly
involves isolating organisms on solid media, assessing the inhibition of bacterial growth for isolated strains
under a series of concentrations of target antibiotic for determining minimal inhibitory concentration
(MIC) [36]. As described by the Clinical and Laboratory Standards Institute (CLSI), antimicrobial resistance
to an antibiotic is classified as “susceptible (S)”, “intermediate (I)”, and “resistant (R)” to an antibiotic,
given the relative relationship between MIC measurements and “breakpoints” that is usually determined
by taking into consideration the clinical outcomes of infections when the antibiotic is used [37]. The
culture-based approach has been widely used and is still used as a “gold standard” test by national and
international surveillance programs for monitoring antimicrobial resistance [36]. However, this method
requires isolation of the target pathogens, growth in pure culture, and incubation, which can be timely
and challenging due to specimen contamination or overgrowth with environment organisms [38].
In the last few decades, molecular methods have been increasingly applied to detect and quantify
antimicrobial-resistant genes as a potentially effective alternative to the gold standard antimicrobial
resistance detection [39]. Real-time polymerase chain reaction or quantitative PCR (qPCR), using
hydrolysis probes to generate a fluorescence signal, enables a “real-time” assessment of DNA
amplification and allows for a quantification of genetic materials in the original sample. qPCR allows for
multiplexing of several targets in a single reaction that provides amplification data in real time. Recent
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work has established this approach is extremely useful to detect opportunistic pathogens in bovine clinical
samples, and has advantages over culture based approaches, especially where samples may have multiple
pathogens present in the presence of normal flora [38]. These same advantages would apply to detection
of genes that confer resistance to antimicrobial therapy in these same types of samples. Detection of
AMR genes within clinical samples (lungs and respiratory swabs) would provide veterinarians and
clinicians with information regarding the presence or absence of these genes within hours, providing
useful information for therapy selection.
Unlike gold standard methods that generate a phenotypic classification of antimicrobial resistance (S,
I, or R), real-time PCR testing generates cycle threshold (Ct) values, which are continuous values
representing the cycle at which the fluorescence signal exceed the threshold value, to estimate the
number of gene copies in the original specimen. To accurately predict the antimicrobial resistance
classification index using a molecular testing method, an extensive epidemiological evaluation using both
methods and a comparison between molecular and gold standard methods must be conducted to ensure
an accurate and valid prediction. The objectives of this study were to (1) develop a multiplexed real-time
hydrolysis probe assay (rtPCR) for the quantification of macrolide and tetracycline-resistant genes found
in BRD clinical specimens; (2) determine the optimal cutoffs to translate a specific Ct value generated by
the rtPCR assay to a phenotypic classification of antimicrobial resistance, and (3) evaluate the validity of
AMR phenotypic classification determined by the rtPCR assay.

2.2

Materials and methods
2.2.1

Sample collection and distribution

Bovine lung tissue and nasal swab samples were collected from the submissions for BRD diagnostic
testing to the University of Nebraska-Lincoln Veterinary Diagnostic Center over one year in 2018 and
combined with an archived sample collection that had been stored at -80˚C from 2012 to 2017.
Although detailed clinical information was not available for many submissions, most of these samples
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were likely collected from non-healthy clinically ill animals. A total of 416 bovine clinical specimens
were collected, primarily consisting of lung tissues (297 specimens) and nasal swabs (111 specimens).
Omitted samples (8 specimens) are either tissues less related to BRD diagnosis or lack of records about
tissue types, which were therefore excluded from further data analysis. The detailed sample
composition is listed in Table 2.1. The specimens were analyzed for the existence of target BRD
bacterial pathogens, which were subsequently determined for their phenotypic AMR characteristics
using a gold standard culture-based method. In addition, the samples were subject to the
quantification of target genes conferring antimicrobial resistance using the culture-independent rtPCR
rapid detection method.

2.2.2

Diagnostic tests

Gold Standard. All clinical specimens were processed for isolating and identifying for the following
BRD pathogens, including M. haemolytica, P. multocida, and H. somni. For each confirmed BRD
pathogen isolate, the antimicrobial resistance was evaluated for the following drug classes using their
respective antibiotics: tetracycline class (oxytetracycline) and macrolide class (tilmicosin and
tulathromycin). As the gold standard approach, antimicrobial resistance to tetracycline and
macrolides were evaluated using the broth microdilution method, which is assessed using CLSI
approved standard MIC index. The MIC breakpoints applied for antimicrobial drugs used in this study
are listed in Table 2.2. As shown in the table, BRD pathogen isolates can be classified as susceptible
(S), intermediate resistant (I), or resistant (R) to each drug. In this study, intermediate resistance and
resistance are both re-defined as “Resistance” (R+I), implying if a specific BRD pathogen was isolated
from a sample and tested I/R/R+I to a specific drug evaluated in this study then the sample is
considered resistant. Also, a sample can be recorded as containing resistant BRD pathogens if at least
one antimicrobial resistant BRD pathogens evaluated in this study was detected.
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Molecular based real-time PCR. A multiplexed real-time PCR (rtPCR) was developed based on known
genome sequences of BRD pathogens (M. haemolytica, P. multocida, and H. somni) to detect the
antimicrobial resistance. Four gene targets were identified, including three that confer resistance to
macrolide drugs (msrE, mphE, and erm42) and one for tetracycline-class drugs (tetH). The results for
the molecular-based rtPCR are provided in the form of a cycle threshold value that ranges from 0 –
40, which is also shown in Figure 2.2 (specifically for the macrolide class). For the tetracycline class
drug, the cycle threshold is observed for tetH, for the macrolide class, for each drug, the cycle
threshold is observed for the three gene targets.

2.2.3

Statistical analysis

Statistical analysis was implemented to optimize and validate the developed multiplex rtPCR assay for
classifying antimicrobial resistance characteristics into either susceptible (S) or “resistant” (R+I).
Firstly, optimal Ct values were determined using receiver operating characteristic (ROC) analyses by
maximizing the assay accuracy (both sensitivity [Se] and specificity [Sp] as the primary accuracy
indices) compared to the gold standard test. Optimal thresholds were determined for clinical
specimens possessing the pathogens M. haemolytica, P. multocida, and H. somni resistant to
oxytetracycline (OTC), tilmicosin (TIL), and tulathromycin (TUL), as well as possessing at least one
resistant BRD pathogens. Secondly, the diagnostic accuracy and validity of the developed rtPCR assay
were assessed by determining the sufficiency of sample size collected in this study for detecting
macrolide and tetracycline resistance in specimens possessing BRD pathogens, as well as using a crossvalidation technique. All statistical analyses were performed in R version 3.5.1 [40].

2.2.3.1

Optimal threshold determination

Data preparation for ROC analysis. For determining the optimal Ct, ROC curves were plotted by
comparing the phenotypic antimicrobial-resistant classification determined by the gold standard
test with the continuous Ct value generated by the multiplex rtPCR assay using the ‘pROC’ package
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in R [41]. As aforementioned, among the samples involved in this study, those containing BRD
pathogens of intermediate resistant (I) were in a relatively small amounts (Table 2.3). For analysis
purposes, intermediate resistance (I) was re-categorized as “resistance” (R+I), resulting in a binary
classification of antimicrobial resistance, i.e., R+I as “resistant” and S as susceptible. ROC curve is
one of the common methods for evaluating diagnostic tests with binary classifiers [42]. But this
method does not work optimally if there is no detection or anomalies observed on either of the
diagnostic tests. In this study, no detection in rtPCR means the target gene is either present in a
very small amount or completely absent. Hence, samples recorded as no gene copies detected
were imputed with a Ct value of 40 that is the highest amplification cycle observed in this study.
For the gold standard tests, it is not easy to reinvestigate missing results as they are quite timeconsuming. As a result, overall, four samples were further excluded, due to the lack of MIC records
for any of the drugs, which resulted in a total of 404 samples (296 lung and 108 nasal) included in
the following data analysis.
ROC analysis to determine optimal Ct threshold. In this study, the ROC curve was generated by
plotting the true positive rate (Se) against false positive rate (1 – Sp) to determine the diagnostic
equivalency between the multiplex rtPCR and the gold standard method over different
thresholds. The schematic representation of the comparison in outcomes of the multiplex rtPCR
assay compared to the culture-based gold standard test and the calculation of Se and Sp is similar
to as shown in Table 1.2 and equation 1.1 and 1.2. The optimal threshold that translates the
continuous Ct value into a binary classification of resistant or susceptible was determined by
optimizing the area under the curve (AUC) [15]. AUC can take values between 0.5 and 1, an AUC
value closer to 1, indicating the high performance of the rtPCR approach of predicting the
resistance classification with minimum classification error when compared with the gold standard
test.
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Performance of rtPCR. As a post-analysis statistic, Cohen’s Kappa ( ) was calculated given the
determined optimal Ct threshold to measure the agreement between the two tests, i.e., gold
standard and multiplex rtPCR assay [43]. The coefficient ranges from -1 to 1, where higher value
of

would imply greater concordance between the two tests. The following interpretation for

Cohen’s

were used here [44]: κ<0.2 implies a poor level of agreement; 0.2<κ≤0.4 indicates a

fair level of agreement; 0.4<κ≤0.6 indicates a moderate level of agreement; 0.6<κ≤0.8
indicates a good level of agreement, and κ>0.8 implies a very good level of agreement.
is calculated using the equation 2.1:
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,

,

) were also

calculated to measure the true positive and true negative results of the multiplex rtPCR assay as
shown in Table IV. In this study,

is the proportion of samples showing test result of ‘R’ based

on the multiplex rtPCR assay which is actually diagnosed as ‘R’ using the gold standard approach,
while

is the proportion of samples showing ‘S’ based on the multiplex rtPCR assay which is

actually diagnosed as ‘S’ using the gold standard approach. As mentioned under Section 1.2,
and

depends on the prevalence of the disease. In general, if the prevalence of the disease is

low, then the possibility of getting false positive cases or lower

increases and when the

prevalence of the disease is high, then the possibility of getting false-negative results or lower
increases [11]. In our study, higher value of

would indicate that the number of samples
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showing ‘R’ based on the multiplex rtPCR assay but diagnosed as ‘S’ using the gold standard are
less and higher value of

would indicate that the number of samples showing ‘S’ based on

the multiplex rtPCR assay but diagnosed as ‘R’ using the gold standard are less.

2.2.3.2

Diagnostic accuracy evaluation

To develop a multiplex rtPCR assay with relative high diagnostic accuracy for classifying
antimicrobial resistance status in clinical specimens, it is contingent on a balance between the
samples with positive and negative responses to the outcomes of interest, i.e., ‘R’ and ‘S’ [8]. To
evaluate if the balance is reached, the minimum required sample size, along with the required
proportion of resistant samples, was estimated and compared with the sample sizes and resistant
samples included in this study to validate the optimal Ct values determined using the ROC
approach.
PPV and NPV, as introduced in Chapter 1, are considered an essential factor for estimating
the required sample size for evaluating diagnostic accuracy, which denotes the total samples,
including those that are resistant and susceptible. The minimum required number of samples
(considering

and

) of importance assuming that the prevalence of the disease (for this

study - the number of cases ‘R’) denoted by C should neither be too small nor too large (C ≠

0

1) are shown in equations 2.2 and 2.3, respectively and are indicated by
EEF
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where X = 0.05 is the significance level, and Z = 0.80 is the power, IJKL and IJKM are the

standard normal values corresponding to X and Z, U < 1 − C, QJ = 4

JK[\
, and Q=
[9

=4

JK[9
[\

16

are the diagnostic likelihood log-ratios for
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, and calculations for

are as shown in equations 1.1 and 1.2. Using equations 2.2 and 2.3 the required minimum

sample size ( ) is then calculated by taking the maximum of

EEF

and

GEF

as shown in equation
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The required proportion of resistant samples can be calculated using equations 2.2 and 2.3 as
shown below in equation 2.5 and is denoted by p* with the assumption that
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are as shown in equations 1.1 and 1.2. Minimum required number of resistant

samples denoted by Nn* can then be obtained as shown in equation 2.6,
Nn∗ =

∗

∗

2. 6

Therefore, to evaluate whether the optimal Ct value determined using the ROC approach is
considered valid if the observed sample size and the proportion of cases ‘R’ is greater than or
equal to the minimum required sample size

and number of cases Nn* .
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Once the sufficiency of the sample size and required number of resistant samples were
determined for detecting the AMR in BRD pathogens, a cross-validation technique was further
used to evaluate the computational approach used in the ROC approach to determine the optimal
Ct value. Cross-validation (CV) is one of the most common resampling methods to assess the
performance of a diagnostic test [45]. Herein K-fold CV technique was used to validate the optimal
Ct value of the multiplex rtPCR assay for classifying antimicrobial resistance equivalent to the gold
standard. In K-fold CV [46], the dataset is split into K equal-sized subsets, the ROC analysis is
conducted on K-1 training sets, and the misclassification error is calculated on the remaining set.
This process is repeated for K times to have an average estimate of the error. Cohen’s was used
to compare the level of agreement between different iteration of K-fold cross-validation. This
technique also helped getting a consistent estimate of the optimal Ct value, which was an average
of all the optimal Ct cutoff obtained across K iterations. The average Ct value is denoted by 1
and is calculated as shown in equation 2. 7.
r

1
= p
o

1

qsJ

q

where K signifies the K-fold cross-validation and
t uv iteration, t = 1, … . , o.
The 1

2. 7
q

denotes the optimal Ct value obtained in the

, the average value along with the standard deviation was also calculated for

both the training and the test set to compare the level of agreement between rtPCR and gold
standard test. Equation 2.8 and 2.9 shows the average kappa ( ) coefficient for both the training
and test set, respectively. The standard deviation of the level of agreement for the training and
test set are calculated using equation 2.10 and 2.11.
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where K and t are same as defined after equation 2.7

2.3

Results
2.3.1

Antimicrobial resistance identified based on the gold standard test

Along with the sample distribution by specimen type, Table 2.1 also shows the prevalence of BRD
pathogens by specimen type. Overall, among the submitted specimens for BRD diagnosis, 97.8% have
at least one BRD pathogen detected. The specimens submitted for BRD diagnosis were expected to
be sicker, and hence higher prevalence was anticipated. In general, the percentage of samples with
at least one BRD pathogen is higher in lung specimens (71%), compared to nasal (26%). Consistent
with the previous reports, M. haemolytica is most frequently detected, comprising 63.7% of tested
samples, followed by P. multocida (42.5%), and H. somni (29.6%). However, the pathogens’
distribution varied by specimen type, as shown in Figure 2.1. Specifically, among lung specimens, M.
haemolytica is the most prevalent pathogen (64.3%), followed by P. multocida and H. somni at a
similar level (32.3% and 31.3%, respectively). Different from lung samples, most nasal specimens
possess both M. haemolytica and P. multocida at a relatively high level (64.9% and 72.1%,
respectively), but not H. somni (26.1%).
The distribution of AMR classification determined by the MIC test was listed by BRD pathogens and
specimen type in Table 2.3. As shown in Table 2.3, the strains classified as intermediate resistant (‘I’)
are much less prevalent than resistant (‘R’) or susceptible (‘S’), and the number of samples in this
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category is too low to allow for powerful statistical analysis. Hence, the category of intermediate and
resistant were combined into “resistant” (R+I), resulting in a binary classification of AMR based on the
gold standard MIC test, i.e., “resistant” (R+I) and susceptible (S). The analysis was done with respect
to a new pathogen category, positive for at least one BRD pathogen, for a equivalent comparison
between results of the MIC test and the rtPCR assay. The primary reason is the two methods (rtPCR
assay, and the MIC test) apply a completely different principle for detecting AMR. In a MIC test, AMR
classification was determined for specific pathogen isolates cultured from the specimen. At the same
time, the rtPCR method is culture-independent; therefore, it cannot differentiate which BRD
pathogens the target genes conferring AMR are from or whether the genes are from bacteria other
than the BRD pathogens. To maximize the rationality for comparing between results from the two
tests, samples were recorded as containing at least one resistant BRD pathogens based on the MIC
test. For the macrolide group, resistance was tested against two drugs, TIL and TUL, and their results
were combined in a similar manner as discussed above. Overall, based on the newly defined
“resistance,” the prevalence of tetracycline-resistant (TETr) BRD pathogens is higher than that of the
macrolide-resistant (MACr) ones, which can be observed for all pathogens and all specimen types. In
addition, the occurrence of antimicrobial-resistant BRD pathogens was always higher for lung
specimens compared to nasal ones. Specifically, 44.6% of lung specimens and 23.1% of nasal
specimens possess at least one TETr pathogens, respectively, while 36.9% of lung specimens and
19.4% of nasal specimens possess at least one MACr pathogens. The same trends have been observed
throughout all resistant BRD pathogens.

2.3.2

Optimal threshold determination

Three gene targets msrE, mphE, and erm42 conferring resistance to the macrolides were tested in the
rtPCR method. Since the objective is to obtain an optimal Ct threshold for each antimicrobial drugusing rtPCR, the average of observed Ct values for three targets were used, which is an acceptable
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substitution. Ct measures for the three genes were plotted and distributed with a high degree of
similarity (Figure 2.2). It was evident from the plot that erm42 and msrE were very close to each other.
Although mphE is slightly higher than the other two, the percentile distribution was similar, so taking
the average of the three target genes would be a good representation of the inherent distribution of
any of the three targets. Hence, all results for macrolide drugs reported in this study are based on the
average measurement of the three gene targets.
The optimal Ct values as shown in Table 2.4 were obtained from the ROC curves by maximizing
the AUC across a series of possible cutoffs based on the comparison between rtPCR measures and
results of the MIC test that defines “resistance” (R+I) and S. Based on a determined optimal Ct,
performance metrics measuring the rtPCR for AMR classification were estimated, including
AUC, Kappa ( ) coefficient, prevalence,

and

,

,

for the isolates evaluated at a power of β =

0.80 and level of significance α = 0.05.
For the lung specimens, the optimal Ct value obtained for the OTC was 36.06, with more than 80%
Se and Sp, with a good level agreement with the MIC test ( =0.64). The prevalence of lung specimens
possessing at least one BRD pathogen resistant to OTC was around 45%, leading to

and

estimates of 79% and 84%, indicating 79% of tested resistant specimens possess at least one BRD
pathogen resistant to OTC and 84% of specimens tested susceptible are truly susceptible. Compared
with detecting OTC resistant BRD pathogens, the optimal Ct value obtained for macrolide drugs are
relatively lower, around 33, with lower

but higher

around 90%. The rtPCR assay has a good level

of agreement with MACr resistance detection using the MIC test, indicated by
0.64. Like OTC resistant detection,
ensuring lower false-negative rate and

ranging from 0.61 to

of MACr resistance detection can reach more than 80%,
almost close to 80%, ensuring a lower false-positive rate.

Thus, the optimal Ct obtained from the ROC approach optimizes both error rates, i.e., false positive
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and false negative, in a well-balanced way. Figure 2.3.1 shows the ROC plots for all the antimicrobial
drugs for the lung specimen.
For the nasal specimen, the optimal Ct values for detecting resistance to OTC and MAC drugs generally
lower than those in lung specimens, ranging from 31.47 to 32.81. In general, the performance of the
rtPCR approach for detecting resistance in nasal specimens is lower, compared to lung specimens.
and

are both lower, ranging 42%-88% and 79%-83%, respectively, and their concordance with MIC

tests is fair to moderate, indicated by

ranging from 0.24 to 0.56. The lower performance might be

related to a lower prevalence of TETr and MACr BRD pathogens isolated in the nasal specimens (11%24%). However, it is worth noting that the higher percentage of susceptible samples likely facilitated
the optimal Ct threshold determination in favor of NPV optimization (close to or higher than 90%),
ensuring a lower false-negative rate. Figure 2.3.2 shows the ROC plots for all the antimicrobial drugs
for the nasal specimen.

2.3.3

Validation of the computational approach

Required sample size determination for calculating the optimal threshold. As mentioned under
Section 2.2.3.2, the optimal Ct was considered valid if the total sample size and the number of samples
positive for resistant BRD pathogens were both greater than or equal to the minimum required total
sample size and number of resistant samples by considering both

and

of some importance.

Estimates necessary for the validity evaluation are listed in Table 2.5.
The optimal Ct obtained for the lung specimen for the tetracycline and macrolide group satisfies
both requirements, i.e., sufficient total sample size and resistant samples. For the nasal specimen,
only the optimal Ct obtained for OTC satisfies both the requirements. The optimal Ct value obtained
for TIL, TUL, and combined macrolide group does not meet the second condition, i.e., the number of
resistant samples included for determining the optimal Ct value is less than the minimum
requirement. It is to be noted that if only NPV is of importance, then the optimal Ct obtained for all
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the nasal specimen are valid, but since in reality, higher PPV or minimizing false-positive rate helps in
reducing the overall misclassification rate although it cannot be ignored completely.
Cross-validation. To validate the consistency of the optimal Ct threshold estimation, 5-fold, and 10fold CV were further conducted.The 5-fold CV gave more consistent estimates in terms of the optimal
CT threshold and the kappa (κ) value and has been used to evaluate the optimal Ct value for the rtPCR
method. Table 2.6 shows the result for a 5-fold CV together with the comparison of the average level
of agreement between the training and the test sets.
The optimal Ct obtained from the lung specimens for both the tetracycline and the macrolide
groups are well-validated in terms of required diagnostic accuracy. In general, for the lung specimens,
the optimal Ct obtained from the overall data lies within the 95% average optimal Ct obtained using
the 5-fold CV. Also, the average

evaluated based on the training and test sets indicates a good level

of agreement with the results of the MIC test. However, the optimal Ct obtained from the nasal
specimen is well validated along with a moderate level of the agreement only for the tetracycline
group, i.e., OTC. The results for the overall effect of the macrolide group shows a disparity in terms of
the average

evaluated on the training and the test dataset.

Summary. Table 2.7 summarizes the optimal Ct values along with the level of agreement, which has
the minimum required sample size and the number of sample sizes for cases and validated using 5fold cross-validation. In summary, the optimal Ct for the lung specimen is well-validated, and for the
nasal specimen, only the optimal Ct obtained for OTC is validated. The optimal Ct obtained for the
lung specimen is 35.66, 33.12, and 32.64 for OTC, TIL, and TUL, respectively, with a good level of
agreement between the gold standard and the rtPCR approach. The optimal Ct obtained for the nasal
specimen is 32.81, with a moderate level of agreement between the gold standard and the rtPCR
approach for OTC.
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3. Chapter 3 – Application of the proposed methodology
3.1

Motivation

The traditional approach for comparing two diagnostic tests when they have different working principles
and outcomes is by using receiver operating characteristics (ROC) curves [12-14]. As mentioned in Chapter
1, the traditional statistical methodology uses area under the curve (AUC) to assess the diagnostic
performance of the two tests. In Chapter 2, the traditional approach was used to determine the optimal
cycle threshold (Ct) value generated by the culture-independent multiplex real-time rtPCR method, and
equivalent to the gold standard results for detecting the antimicrobial resistance caused due to common
bovine respiratory disease (BRD) pathogens. The optimal Ct value produced by the multiplex rtPCR that
translates to either antimicrobial resistance (‘R’) or susceptible (‘S’) was estimated by optimizing the AUC.
AUC is represented as the summary over all possible thresholds of sensitivity (

) and specificity (

)

which is one of the prime reasons for the widespread use of AUC as a tool for measuring diagnostic
accuracy [47, 48].
However, higher AUC values do not necessarily mean a good predictive accuracy or lower
misclassification error [47, 49]. AUC is designed in a way that it ignores the actual probability values and
discriminates between the two classes by considering the order of the probability values [50], which
makes it unfit to be considered as a goodness – of – fit measure. Moreover, the way AUC evaluates the
classification rule is not independent of the classifiers itself, i.e., for this study, the classification rule for
evaluating resistance and susceptibility are not compared using the same metric [51]. It is the conceivable
flaws of AUC that led to the motivation for this chapter, which is to find an alternative and efficient
approach to compare two diagnostic tests with an overall good predictive precision and thereby
minimizing the misclassification error.
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3.2

Materials and methods

A total of 416 samples mostly of lungs (297) and nasal (111) from cattle were collected from the University
of Nebraska, Lincoln Veterinary Diagnostic Center (UNLVDC). These samples were used to evaluate
antimicrobial resistance to the most common bacterial pathogens (M. haemolytica, P. multocida and H.
somni) causing Bovine Respiratory disease (BRD) by using the culture-based and culture-independent
diagnostic tests against antimicrobial drugs belonging to the tetracycline (oxytetracycline or OTC) and
macrolide groups (tilmicosin or TIL and tulathromycin or TUL). For the culture-independent multiplex
rtPCR, tetH confers resistance to the tetracycline group and msrE, mphE, and erm42 confer resistance to
the macrolide group. Table 2.1 provides information regarding the distribution and prevalence of the
bacterial pathogen among each type of sample specimen. All of the statistical analyses were done using
R [40].

3.2.1

Data preparation

In Chapter 2, lung and nasal specimens were analyzed separately by considering the MIC results as a
response, and the cycle threshold obtained from the rtPCR method as the only predictor. Any other
relevant information that could have led to antibiotic resistance was not included in the analysis. Thus,
in the current study, prior treatments administered to the cattle antemortem were added to enhance
the accuracy of the proposed methodology. It was hypothesized that incorporating the information
of multiple drug treatments and vaccination will improve the predictability of the model.
A similar imputation technique, as mentioned under Section 2.2.3.1, was applied for the Ct value
generated from the multiplex rtPCR. The missing Ct values were imputed with the highest
quantification cycle 40. For the gold standard result, no imputation was applied for the missing values.

3.2.2

Model development

Logistic regression [52] was used to determine the association between the two diagnostic tests. The
response was a binary classifier (‘R’ denoting resistance and ‘S’ denoting susceptibility) observed from
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the gold standard method for each drug (OTC, TIL, and TUL). The primary explanatory variable of
interest or predictor is the Ct value generated by the target genes for each drug class (Tetracycline
and Macrolide). The analysis in Chapter 2 included the same pair of response and predictor, and it
was done separately for the lungs and nasal sample.
For the current chapter, to improve the model efficiency, the following steps were implemented:
•

The analysis was done together for the lung and nasal samples

•

Feasibility and significance of additional predictors were tested

The first model, referred to as the “Baseline Model,” considers the target gene as the only predictor
({). The second model, referred to as the “Model 1,” considers the sample type (i.e., lungs and nasal)
as a predictor (I) along with the targeted genes. The third and the final model referred to as the
“Model 2”, also included a third predictor (|), the number of drugs administered to the cattle
antemortem. The three logistic models are shown in equation 3.1 – 3.3.
4
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The response is denoted by } and the logit is the natural logarithm of odds of }. € indicates the
probability the sample is resistant (‘R’).
Resampling methods were used to compare the models and evaluate the prediction accuracy [53].
The data set was repeatedly split into training and test sets using stratified sampling to assess the
accuracy of the model fit. The multiple iterations of the resampling process facilitated an examination
of the variability of the results for different pairs of training and test sets. The model was trained
using each training set and the performance measure was evaluated based on the corresponding test
set. The individual performance measures are aggregated by calculating the mean across all the
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iterations. Model comparison and selection for each drug were decided based on Akaike’s information
criterion (AIC) [54], AUC, and average accuracy. ROC curve by default considers the probability
threshold of 0.5 for interpreting the classifiers. In this case, if the predicted probability is greater than
0.5, then the sample is considered resistant; otherwise, it is susceptible. These will result in
misclassification of classes resulting in false positive or false negative cases. Error rate and accuracy is
then calculated using the following formula shown in equation 3.4 and 3.5, where TP, FP, TN and FN
can be referred to Table 1.1.
ƒ
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3. 4

3. 5

A general rule of thumb that was used for model selection was lower average AIC, higher average
AUC, and higher average accuracy. The optimal Ct evaluated from the 0.5 thresholds was used to
calculate the level of agreement ( ) in the training and test dataset. The level of agreement denoted
by

was defined under Section 2.2.3.1.

3.2.3

Prediction and H measure approach

AUC is one of the most widely used measures for evaluating the effectiveness of a classification
criterion and diagnostic accuracy. One of the most significant advantages of AUC is that it is
independent of any user input. For a given set of data, AUC is the same irrespective of other factors.
However, AUC has a more fundamental weakness. AUC measures the classification performance using
the classifiers itself [51]. Moreover, AUC lacks severely in optimizing the threshold probability to
minimize the misclassification error. It is for this reason that an alternative measure to AUC is
introduced in this section.
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The alternative measure named “H measure” is a more simplified approach that combines the

relationship between the misclassification cost (28 , 2J ) and the predicted probability scores. The
distribution of the scores (3 2)) is assumed to follow a beta distribution, as shown in equation 3.6.
3 2) = 3L,M
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0 is equivalent to misclassification cost incurred while

misclassifying ‘S.’ Misclassification cost for 24

1 is equivalent to misclassification cost incurred

while misclassifying ‘R’. The general misclassification loss function evaluated at the optimal threshold
is given by •
•

2); , 2) and is shown in equation 3.7,
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where €8 and €J signifies the prevalence of ‘S’ and ‘R’ respectively and is the cumulative distribution

function for the score 3 2) one for each class as denoted by the subscripts. The expected general loss
function (‘) is then defined as (equation 3.8),
‘L,M = ‡ •
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= 28 + 2J and 3L,M 2), 2 is as defined in equation 3.6. Using equation 3.6 – 3.8, the H

measure is calculated as,
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Like other standard coefficients, H lies between 0 and 1 with a higher value, usually meaning a
good fit of the model. It is to be noted that AUC and H are not monotonically associated. Unlike AUC,
H measure depends on the prevalence of the classes, i.e., the proportion of ‘R’ and ‘S’ in this case.
This enables the statistic to have a comparable measure to evaluate the misclassification loss. The
‘hmeasure’ package in R was used to implement this analysis [55].
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Although the H measure has been simplified and made independent of any subjective input, the
researcher still has the flexibility of choosing the threshold as per the research interest. For a threshold

of = 0.5, the misclassification matrices produced by AUC and H measure are the same. The overall
misclassification error is handled differently if

≠ 0.5. The overall error is either optimized by

minimizing the false positive cases or by minimizing the false-negative cases. Which type of
misclassification is more serious is subjective and depends on the situation. Generally, for diagnostic
tests, recognizing an existing condition as having no condition is more expensive in the long run as
compared to misclassifying no condition as an existing condition. In other words, for the current study,
it is desirable to minimize the

or misclassifying ‘R’ as ‘S.’ The desired

resulting confusion matrix can be achieved for the equivalent

level can be fixed, and the

level. The package also has an option

of specifying the severity ratio (SR), which is the misclassification cost of one error over the other. In
this case, it can be referred to as the misclassification cost of ‘R’ over the misclassification cost of ‘S.’
During the resampling process, the probability threshold is selected during the training process
based on the minimum error rate (MER). Once the threshold is selected, it is applied to the test
dataset to evaluate the misclassification error. Like equation 3.4, the average accuracy based on the
threshold selected using H measure is calculated for evaluating the model performance. In addition
to the performance measure mentioned under Section 3.2.2, average accuracy calculated using the
optimal threshold (evaluated from H measure) is also considered for model selection. Once the
thresholds were determined and the optimal Ct value evaluated,

was used to measure the level of

agreement.

3.3

Results
3.3.1

Data preparation

A categorical variable for the number of drugs administered to the cattle was created by summarizing
the available prior treatment information. Table 3.1 shows the distribution of the four categories of
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the number of drugs administered to the cattle. Out of 416 samples, around 63.7% of the samples did
not have relevant information available in terms of drug count. For 33.9% of samples, relevant
information was available. The variable was found out to be significant in model 2, as mentioned
under Section 3.2.2. A dummy variable regarding vaccination administered to the cattle antemortem
was also created. Vaccination information was sparsely available, with 75% of samples having
negative or no information offered. Due to the high proportion of negative vaccination records, the
variable was not found to be significant in any of the models. Table 3.2 shows the distribution of the
three categories of the vaccination status of the cattle antemortem.
For the gold standard result, approximately 2-4% of observations were missing for each drug.
Since no imputations were done, case – deletion approach was undertaken wherever the gold
standard results were missing. Table 3.3 shows a comparison of average Ct and standard deviation for
the gene targets generated from the multiplex rtPCR before and after the imputation with the highest
quantification cycle. As expected, the average Ct value increased for the gene targets with the
maximum increase observed for erm42 followed by mphE, msrE and tetH.

3.3.2

Model selection and prediction accuracy

The resampling process was tried for multiple iterations up to 40 repetitions. The average of the
model performance was calculated based on the iterations. Three different models, as mentioned
under Section 3.2.2, were executed for each drug, and the model performances are listed under Table
3.4. Model 2, which included the continuous cycle thresholds, sample type, and drug count
administered antemortem to the cattle as a predictor, was observed to have the best performance
for all the drugs, i.e., OTC, TIL, and TUL. Model 2 had the lowest average AIC, highest average AUC,
and highest average H value based on the training set. The average accuracy was calculated both using
the threshold of the AUC approach ( = 0.5) and the threshold selected using the H measure

approach. The average accuracy calculated on both the training and test dataset gave consistent
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results like AIC and AUC using = 0.5 for all the drugs. Using the H measure approach, the baseline
model had the best average accuracy. Overall, the accuracy calculated using the H measure was
consistently lower for all the models. Figure 3.1.1 – 3.1.3 shows the comparison of the average
accuracy over the 40 iterations for all the three models. The difference in accuracy using the two
approaches is observed more for OTC, followed by TUL and then TIL. The average accuracy using H
measure is observed to be lower than the AUC approach. All the three figures for OTC and TIL show
that approximately after 20 iterations, the average accuracy is stabilized, while for TUL, it took around
30 iterations to stabilize especially for the accuracy using the H measure approach.
For all the drugs, model 2 seems to be a better choice overall in terms of the model performance
and the average accuracy. As mentioned under Section 3.2.3, the threshold using H measure was
selected based on the minimum error rate calculated on the training set. Table 3.5 shows the
threshold along with the comparison of minimum error rates calculated using both approaches. The
threshold estimated using the H measure lies between 0.41 – 0.44 for OTC, 0.49 – 0.53 for TIL, and
0.47 – 0.52 for TUL. All the models had a threshold of less than 0.5 except the two baseline models
for TIL and TUL. The average minimum error rate possible using H measure was lower than the average

error rate produced by the AUC approach ( = 0.5). Although in this study, using = 0.5 lead to a
better average accuracy, as indicated by Table 3.5, the threshold generated using H measure has the
potential to have a better error rate. The analysis for H measure was done with the objective of
minimizing the overall error.
The analysis can also be done by fixing the

= 95% and accordingly generating the error rate

and threshold. It is important to note that the error rate obtained by fixing

might not be the

minimum error rate possible. Another way of doing the analysis is by specifying the severity ratio, i.e.,
if the researchers have an idea of the cost of misclassification of each type of error. For each type, the
threshold would vary, and consecutively the error rates would also vary.
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3.3.3

Evaluating the level of agreement and optimal cycle threshold

Once the probability thresholds were selected, they were used to calculate the optimal cycle
threshold along with the level of agreement . Table 3.6 summarizes the optimal Ct evaluated using
the two approaches and the level of agreement evaluated on the training and the test dataset. For
OTC, using the AUC approach model 1 and model 2 had a good level of agreement in both the training
as well as the test dataset. TIL and TUL had a moderate level of agreement using the AUC approach.
Consistent with the average accuracy results, as shown in Table 3.4, the baseline model’s had the best
level of agreement as compared to the other two models. For H measure, there is a moderate level
of agreement between the two diagnostic tests.
The optimal Ct value for OTC is slightly higher when evaluated using the H measure approach. It

ranges between 33.54 and 34.59, whereas the optimal Ct evaluated using = 0.5 ranges between
31.68 and 32.46. For TIL, the baseline model has a higher optimal Ct using the AUC approach. For TUL,
the difference in the optimal Ct value evaluated using the two methods are minimum, and this is also
reflected in the level of agreement. The main reason for this would be that the average threshold
estimated using H measure is very close to 0.5.
To summarize, model 2 has the best accuracy for all the drugs using the AUC approach, and the
baseline model has the best accuracy for all the drugs using the H measure. The average probability

threshold was estimated to be below 0.5 in most cases except the baseline model for TIL and TUL,

which was greater than 0.5. The optimal Ct values of the best model in terms of accuracy, using both
approaches are summarized in Table 3.7.
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4. Chapter 4 – Comparison of the two methods
4.1

Discussion

The overall objective of this study was to establish a benchmark to evaluate the antimicrobial resistance
genes based on the multiplex real-time PCR assay. The conventional method using the ROC curve and AUC
was used in Chapter 2, and the proposed method, which is a combination of the fixed-effect generalized
model and H measure, was used in Chapter 3. The basic idea behind the two methods is similar, yet they
are fundamentally different from each other.
Firstly, the traditional method used in Chapter 2 requires doing the analysis separately for each
specimen type, i.e., the lung and nasal samples. The method also does not involve any other predictors
other than the continuous cycle threshold (Ct) value generated based on the multiplex rtPCR. In a
modification to the existing approach, the proposed methodology in Chapter 3 includes additional
predictors like the specimen type (lungs and nasal) and the number of drugs administered to the cattle
antemortem. Since the specimen type was included as a predictor, a single optimal threshold can be
estimated for each drug (OTC, TIL, and TUL) instead of doing the analysis separately for each specimen
type. This would also solve the issue of the less sample size and lower proportion of resistant cases (‘R’)
amongst the nasal samples. Also, as shown in Table 3.4, the model with the two additional predictors had
a lower AIC value indicating a good fit.
Secondly, the traditional approach uses area under the curve (AUC) from the ROC curve to
estimate the optimal Ct based on the multiplex rtPCR assay. AUC is one of the simplest and widespread
methodologies used for evaluating classifiers. It is very easy to use and does not require any additional
inputs from the user. By default, AUC uses the probability threshold of 0.5 to categorize the predicted
probability into the required classes. For this study, a probability greater than 0.5 was classified as
resistant (‘R’), and less than or equal to 0.5 were classified as susceptible (‘S’). This potentially can be
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problematic for studies where the prevalence (for cases, i.e., ‘R+I’ here) is either very low or very high
[47]. In either case, considering a probability threshold of 0.5 to discriminate between the two classes
does not seem very appropriate. This could be a potential reason why the optimal Ct obtained using the
nasal samples were not validated. As observed in Table 2.4, the prevalence of antimicrobial resistant
genes among the nasal samples was between 10.2% and 23.2%, which was lower than the prevalence
among the lung samples (32.1 – 44.6%). In the proposed approach, the disparity in the prevalence is solved
by combining the lung and nasal specimens together. The overall prevalence used in Chapter 3, for OTC,
is 39.1%, TIL is 28.1%, and TUL is 27.8%. Even after adjusting the prevalence for the cases, using a threshold
of 0.5 for classification still does not seem very appropriate. This might lead to an increase in false
negativity (

), which would eventually decrease the

and

of the test. The H measure function in

the proposed approach would offer a resolution in that area.
Third, as mentioned in Chapter 3, AUC discriminates between classes purely by ordering the predictive
scores and completely disregards the relative weights or costs of correct and incorrect misclassification.
Further, as mentioned in [51], for the same classification rule, AUC uses different cost distributions for
different classifiers. The implication of this in our study will indicate that the cost distribution used for ‘R’
and ‘S’ will vary for each drug and model since the cost distribution would depend on how the classifiers
are distributed in each dataset. In reality, the misclassification cost would depend on the research interest
and not on the classifiers themselves. H measure was proposed in [51] to deal with this fundamental
incoherency of AUC. H measure uses a continuous beta function as the cost weight distribution as
compared to the discrete cost weight distribution used in AUC. Figure 4.1 shows a comparison of the cost
weight distribution used in AUC and H measure for two of the models for the same drug used in Chapter
3. Clearly, the cost distribution used by AUC in both the models is very different from each other, as
indicated by Figure 4.1 (a) and (b). This raises a lot of ambiguity in using AUC as a classification criterion
since there is hardly any consistency in terms of the weights considered for misclassification cost. On the
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other hand, the cost distribution for H measure was represented using a beta distribution, which is very
similar to each other. There are other known disadvantages of AUC as well. It does not work very well for
concave ROC curves and in cases of multiple ROC curves crossing each other. For our study, we do not
anticipate any such issues. The primary concern for using AUC as a classification criterion will be that it
does not include the classification cost as a criterion while classifying and blindly uses the probability
threshold as 0.5 for classification. One thing to note is the results for AUC and H measure are not
comparable since they use different functions for classification. This is a probable cause for the difference
in accuracy observed between AUC and H measure in Table 3.4. Since the cost function used in H measure
seems more logical and consistent, it will be sensible to adopt H measure together with the AUC approach.
The research or the problem at hand should dictate which probability threshold to adopt for classification.
H measure lets the user chose the threshold that will yield the minimum error rate, which may or may
not be like the default threshold of 0.5 as used in AUC. As shown in Table 3.5, none of the models chose
0.5 as a threshold. Based on the research interest, the researcher can compromise on the minimum error
rate and decide to choose a different threshold that would minimize either the false positivity or false
negativity. This opens a lot of potential for usage of these methods, especially in diagnostic evaluation.
For example, let’s say for a given research problem, the probability threshold of 0.5 is identified to have
the minimum error rate (MER) of 16.7%. Now, the error rate includes both false-positive rate (FPR) as well
false-negative rate (FNR), which was 5.8% and 10.9%, respectively. At a threshold of 0.39, the overall error
decreases slightly to 16.5%, but the FPR increases to 7.2%, and FNR is decreased to 9.3%. The researcher
can decide which threshold to use based on the requirement, problem area, prevalence observed, and
other reasons relevant to the research problem. While choosing the threshold might be an iterative and
cumbersome process as it would require additional computation of the FPR and FNR, the researcher also
has the option of specifying the desired sensitivity (

) or specificity (

). Since

and

cannot be

optimized simultaneously, the user can specify one of them and the other will be evaluated accordingly.
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In addition to specifying the probability threshold,

or

, the ratio of the cost of misclassification of

the class of interest (also called severity ratio) can also be specified provided the cost of misclassification
is known.
In our study, after combining the lung and nasal samples together, using the resampling method, better
accuracy is observed using a probability threshold of 0.5. The difference in accuracy is strikingly different
for OTC, which could be mainly due to the prevalence of resistant cases at 39%. Since the prevalence is
closer to 50%, using a threshold as used in AUC had better accuracy as compared to H measure, which
had an average probability threshold of around 0.42 – 0.44. For TIL and TUL, the prevalence of resistant
cases was lower as compared to OTC, and it was observed that the difference in the accuracy using the
AUC and H measure are also quite marginal. Especially for TUL, which had the minimum prevalence, the
accuracy between the two methods was almost very close to each other. In terms of the level of
agreement, for TIL and TUL, both methods indicated a moderate level of agreement between the gold
standard and the rtPCR based assay. For OTC, the optimal Ct generated using the AUC approach had a
good level of agreement, whereas the H measure approach indicated a moderate level of agreement. The
optimal Ct identified for OTC, TIL, and TUL based on a combined factor of accuracy, level of agreement,
and probability threshold can be selected using Table 3.7. The final selection can be made by:
•

Average optimal Ct: - OTC – 32.87, TIL – 32.03, TUL – 32.62. Taking an average is more reasonable
and minimizes the risk of increasing either false negative or false positive.

•

Maximum optimal Ct: - OTC – 33.54, TIL – 32.52, TUL – 32.99. If the optimal Ct is lower, then
considering the maximum as an optimal Ct might have a risk of increasing the false negative.

•

Minimum optimal Ct: - OTC – 32.19, TIL – 31.53, TUL – 32.25. If optimal Ct is higher, then
considering the minimum as an optimal Ct might have a risk of increasing the false positive.
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5. Chapter 5 – Summary & Future Research
5.1

Summary of the results

The conventional methodology using the ROC curve and AUC approach was conducted separately for the
lung and nasal specimens. The gold standard results are considered as a response, which was evaluated
basis the prevalence of the number of resistant cases. The rtPCR results are considered as the only
predictor. The prevalence of resistant BRD pathogens among the lung samples for OTC is 44.6%, for TIL is
34.2%, and for TUL is 32.1%. The prevalence of resistant BRD pathogens among the nasal samples for OTC
is 23.1%, for TIL is 10.2%, and for TUL is 14.8%. The optimal cycle threshold based on the rtPCR method
having accuracy equivalent to the gold standard method is evaluated using the AUC approach. The
average optimal cycle threshold based on the 5-fold cross-validation approach for lung samples are OTC
– 35.66, TIL – 33.12, and TUL – 32.64. The level of agreement ( ) between the two diagnostic tests is
calculated using the average optimal cycle threshold based on the 5-fold cross-validation approach. For
lung samples, the level of agreement is OTC – 0.61, TIL – 0.61, and TUL – 0.63. For all three drugs, using
lung samples, there is a good level of agreement between the gold standard and the rtPCR method. Since
the prevalence of resistant BRD pathogens is considerably smaller for TIL and TUL, the optimal cycle
threshold cannot be validated in terms of the required sample size and number of resistant cases. The
optimal cycle threshold for OTC using the nasal samples is estimated as 33.27, with a moderate level of
agreement (0.49). Although this satisfies the minimum required sample size and number of resistant
cases, considerable variability is observed among the levels of agreement during 5 – fold cross-validation
with a standard deviation of 0.04 among the training and 0.19 among the test data sets. Overall, using the
conventional approach, only the results for lung samples can be validated.
The alternate approach is a modification of the conventional method where three different
models were tested. The baseline model is similar to the model used in the conventional approach, the
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difference being the sample types are combined here instead of doing the analysis separately for lung and
nasal samples. Model 1 has an additional predictor of sample type other than the rtPCR results, and Model
2 has a third additional predictor related to prior drug treatment applied to the cattle antemortem. After
combining the lung and nasal samples, the prevalence of the resistant cases for OTC was 39.1%, for TIL
was 28.1%, and for TUL was 27.8%. In addition to estimating the optimal cycle threshold using the AUC
approach, it is also calculated using the H measure approach. AUC approach uses the default probability
threshold of 0.5 for estimating the optimal cycle threshold. H measure depends on the prevalence of
resistant cases and misclassification costs. The probability threshold for H measure is determined using
the minimum error rate. In terms of AUC, Model 2 has the best accuracy for all three drugs. The average
optimal cycle threshold estimated for OTC is 32.19, for TIL is 32.52, and for TUL is 32.99. The level of
agreement between the two diagnostic tests is 0.63 for OTC and 0.58 for TIL and TUL each. Compared to
the conventional method, the level of agreement shows an improvement for OTC, but for TIL and TUL,
the level of agreement is lower than the one observed in the case of lung samples. For H measure, the
baseline model has the best accuracy for all three drugs. For H measure, the average probability threshold
using 40 iterations is estimated as 0.44 for OTC, 0.53 for TIL, and 0.52 for TUL. The average optimal cycle
threshold determined for OTC is 33.54, for TIL is 31.53, and for TUL is 32.25. The level of agreement
between the two diagnostic tests is 0.58 for OTC, 0.52 for TIL, and 0.56 for TUL. For this study, the
alternative approach and the threshold using AUC had overall better accuracy and a good level of
agreement between the two diagnostic tests.

5.2

Future Research

The current study shows a lot of potential and would need further research and exploration in the
following areas:
•

Overall the study shows that the alternative approach is more consistent and reliable irrespective
of using AUC or H measure than the conventional method. Treatment history, especially the drug
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usage antemortem, was significant in determining the optimal cycle threshold based on the rtPCR.
This shows that if more information on confounding factors (vaccination, detailed drug usage,
etc.) is available, that might help in increasing the predictive accuracy as well as the level of
agreement between the two diagnostic tests.
•

The current analysis was conducted on post-mortem samples, hence taking samples from the lung
was viable. But on live animals, the only feasible option to test for AMR is from nasal swabs. The
current study explored the nasal samples separately for the conventional approach using AUC
only. The prevalence of the resistant cases in nasal swabs was very low, because of which the
optimal cycle threshold was not even validated for TIL and TUL. It will be worthwhile to analyze
the results from nasal swab only using H measure, which depends on prevalence and check if it
can improve the level of agreement between the two diagnostic tests.

•

Although in the alternative approach H measure did not have better accuracy than the one
observed in the AUC approach, H measure has a lot of potential that can be explored if a clear
direction is provided. In most cases, the primary research objective is to minimize either false
positive or false negative; the overall error is under considerable variation. H measure will be
more appropriate to use as compared to AUC since the researcher can specify the required

or

and accordingly determine the probability threshold rather than choosing a default probability
threshold of 0.5.
•

The current study includes one and three target genes for the tetracycline and macrolide group,
respectively. In the event of the identification of more specific resistant genes, the model can be
further developed by incorporating that additional genetic information. However, the discovery
of resistant genes is an ongoing process; thus, there will always be some overlap between the
phenotypic gold standard and the genotypic rtPCR results. This may prohibit the achievement of
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an optimal cycle threshold that will perfectly discriminate between the resistant and susceptible
genes.
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6. List of tables
Table 1.1: 2x2 Contingency Table
Disease or Illness

Diagnostic Test
Results

Present

Absent

Positive

True Positive (TP)

False Positive (FP)

Negative

False Negative (FN)

True Negative (TN)

41

Table 1.2: 2x2 representation of the results of gold standard and the novel diagnostic test
on same subjects.
Gold Standard

“Novel”
Diagnostic Test

Positive

Negative

Positive

J

=

Negative

‚

–
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Table 2.1.. Sample distribution by clinical specimen type and pathogens
Specimen
Type1
Lung
specimen
Nasal
specimen
Others –
skin/liver
Missing3
Total

Total
Samples2
297
111
4
4
416

Occurrence of BRD Pathogens
No. of positive samples (prevalence, 95% CI)
M. haemolytica
191 (64.3%,
58.7 – 69.5%)
72 (64.9%,
55.6 – 73.1%)
1 (25.0%,
4.6 – 69.9%)
1(25.0%,
4.6 – 69.9%)
2654 (63.7%,
59.0 – 68.2%)

P. multocida
96 (32.3%,
27.3 – 37.8%)
80 (72.1%,
63.1 – 79.6%)
0 (0.0%,
0.0% – 49.0%)
1(25.0%,
4.6 – 69.9%)
1774 (42.5%,
37.9 – 47.3%)

H. somni
93 (31.3%,
26.3 – 36.8%)
29 (26.1%, 18.9 –
35.0%)
1 (25.0%,
4.6 – 69.9%)
1(25.0%,
4.6 – 69.9%)
1234 (29.6%,
25.4 – 34.1%)

At least one BRD
pathogens
296 (99.7%, 98.1
– 100.0%)
108 (97.3%, 92.4
– 99.1%)
2 (50%,
15.0 – 85.0%)
1 (25.0%,
4.6 – 69.9%)
407 (97.8%, 96.0
– 98.9%)

1Lung

specimens refer to lung tissues and abdominal fluid clinical samples; nasal specimens are collected as nasal swabs; other
specimens are either skin or liver tissues; missing specimens are those lacking records about tissue types and lacking BRD
pathogens detection results.
2The

distribution of the samples by the pathogens are not exclusive, as more than one pathogen can be isolated from a single
specimen.
3Missing

specimens were not included in further analysis

4A total of 416 samples with recorded results of BRD pathogen detection was used for prevalence and 95% confidence interval
estimation.
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Table 2.2. Phenotypic classification of antimicrobial resistance based on minimum
inhibitory concentration measurements by antibiotics tested in this study.
Class

Antibiotics

Tetracycline
Macrolides

Oxytetracycline
Tilmicosin
Tulathromycin

Antimicrobial resistance classification
Susceptible
Intermediate
Resistant
(S)
(I)
(R)
≤2
> 2 & ≤8
>8
≤8
> 8 & ≤32
>32
≤16
> 16 & ≤32
>32

“Resistant”
(R+I)
>2
>8
>16

Nasal

Lung

Specimen
OTC (TET )
TIL
TUL
MACr
OTC (TETr)
TIL
TUL
MACr

r

Antimicrobials1
296
295
296
295
108
108
108
108

# Total
Samples
R
124 (41.9%)
95 (32.2%)
87 (29.4%)
105 (35.6%)
23 (21.3%)
11 (10.2%)
11 (10.2%)
19 (17.6%)

# (percentage) of samples with2
I
R+I
8 (2.7%)
132 (44.6%)
6 (2.0%)
101 (34.2%)
8 (2.7%)
95 (32.1%)
4 (1.3%)
109 (36.9%)
2 (1.8%)
25 (23.1%)
0 (0.0%)
11 (10.2%)
5 (4.6%)
16 (14.8%)
2 (1.8%)
21 (19.4%)

S
164 (55.4%)
194 (65.8%)
197 (67.9%)
182 (63.1%)
83 (76.9%)
97 (89.8%)
92 (85.2%)
87 (80.6%)

R, I denotes to susceptible, resistant, and intermediate resistant to the drug classified based on MIC test and CLSI breakpoints, and the
categories of R and I are combined into a new category of “resistant”, or R+I.

2S,

refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and tulathromycin,
two drugs tested for resistance that belong to the class of macrolides. MACr is used to indicate the samples that resistant to either tilmicosin or
tulathromycin.

1OTC

At least
one BRD
pathogen

Pathogens

Table 2.3. Summary of MIC results by Specimen type, Pathogens, Antimicrobials, and resistance to
the antimicrobials
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Nasal

Lungs

Specimen

108
108
108
108

OTC (TETr)
TIL
TUL
MACr

296

TUL
295

295

TIL
MACr

296

# Total
Samples

OTC (TETr)

Antimicrobials1

21

16

11

25

109

95

101

132

R+I

87

92

97

83

186

201

194

164

S

# Samples with2

31.82

31.47

31.82

32.81

33.08

32.89

33.08

36.06

Optimal Cycle
Threshold (Ct)4

42.86

43.75

63.64

88.00

67.89

72.63

69.31

81.06

Sensitivity
(%)

82.76

83.70

82.47

79.52

91.40

90.55

89.69

82.93

Specificity
(%)

57.85

57.54

71.42

90.07

81.94

84.29

81.25

85.29

AUC3 (%)

0.24

0.24

0.30

0.56

0.62

0.64

0.61

0.64

Kappa
( )

19.44

14.81

10.19

23.15

36.95

32.09

34.24

44.59

Prevalence
(%)

37.50

31.82

29.17

56.41

82.22

78.41

77.78

79.26

PPV4
(%)

85.71

89.53

95.24

95.65

82.93

87.50

84.88

84.47

NPV4
(%)

– Area under the curve

= Positive Predictive Value;

3AUC

4

= Negative Predictive Value

2S, R, I denotes to susceptible, resistant, and intermediate resistant to the drug classified based on MIC test and CLSI breakpoints, and the categories of R and I are combined
into a new category of “resistant”, or R+I.

refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and tulathromycin, two drugs tested for resistance
that belong to the class of macrolides. MACr is used to indicate the samples that resistant to either tilmicosin or tulathromycin.

1OTC

At least one
BRD
pathogen

BRD
Pathogen

Table 2.4. Optimal Cycle Threshold (Ct) value by Specimen type and Antimicrobials
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Nasal

Lungs

Specimen
OTC (TETr)
TIL
TUL
MACr
OTC (TETr)
TIL
TUL
MACr

Antimicrobials1
296
295
296
295
108
108
108
108

# Total
Samples
132
101
95
109
25
11
16
21

R+I
164
194
201
186
83
97
92
87

S

# Samples
with2
Optimal
Cycle
Threshold
(Ct)
36.06
33.08
32.89
33.08
32.81
31.82
31.47
31.82
Sample
Size
25
30
28
30
22
48
110
123

Proportion
of Cases
18%
18%
17%
17%
16%
26%
33%
35%

Number
of Cases
4
6
5
5
3
12
37
42

Required Sample Size considering PPV3
Sample
Size
23
11
10
14
7
2
2
3

Proportion
of Cases
44%
31%
32%
29%
52%
33%
25%
25%

Number
of Cases
10
3
3
4
4
1
0
1

Required Sample Size considering NPV3

required sample size and the proportion of resistant samples (R+I) calculated considering

and

and

YES
YES
YES
YES
YES
NO
NO
NO

Validated4

of importance to calculate

of importance, respectively.

takes value “YES” if the total sample size and number of resistant samples are both sufficient when considering both
the optimal threshold based on sensitivity, specificity and prevalence

4Validate

3Minimum

R, I denotes to susceptible, resistant, and intermediate resistant to the drug classified based on MIC test and CLSI breakpoints, and the categories of R and I are
combined into a new category of “resistant”, or R+I.

2S,

refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and tulathromycin, two drugs tested for
resistance that belong to the class of macrolides. MACr is used to indicate the samples that resistant to either tilmicosin or tulathromycin.

1OTC

At least
one BRD
pathogen

BRD
Pathogen

Table 2.5.. Assessment of sufficiency of sample size for determining the optimal cycle threshold value
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Nasal

Lungs

Specimen

MACr

TUL

TIL

OTC (TETr)

MACr

TUL

TIL

OTC (TETr)

Antimicrobials1

194

101

87

21

97

11
92

83

25

16

186

109

201

164

132

95

S

R+I

# Samples

31.82

31.47

31.82

32.81

33.08

32.89

33.08

36.06

Optimal Cycle
Threshold (Ct)

0.24

0.24

0.30

0.56

0.62

0.64

0.61

0.64

Kappa (κ)

Overall Data

35.66 (34.8 –
36.5%)
33.12 (33.0 –
33.2%)
32.64 (32.2 –
33.1%)
33.12 (33.0 –
33.2%)
33.27 (32.4 –
34.2%)
31.83 (31.6 –
32.1%)
36.10 (32.4 –
39.8%)
33.30 (30.4 –
36.2%)

Average Optimal
Cycle Threshold
(Ct) (95% CI)

0.20

0.10

0.31

0.56

0.61

0.65

0.61

0.64

Average Kappa
(κ) on Train
Data

0.13

0.18

0.04

0.04

0.02

0.03

0.04

0.04

Standard
deviation Kappa
(κ) on Train
Data

5 – Fold Cross-Validation

0.09

0.01

0.26

0.46

0.61

0.62

0.60

0.61

Average Kappa
(κ) on Test Data

R, I denotes to susceptible, resistant, and intermediate resistant to the drug classified based on MIC test and CLSI breakpoints, and the categories of R and I are
combined into a new category of “resistant”, or R+I.

2S,

0.12

0.09

0.16

0.19

0.09

0.12

0.14

0.17

Standard
deviation Kappa
(κ) on Test Data

refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and tulathromycin, two drugs tested for
resistance that belong to the class of macrolides. MACr is used to indicate the samples that resistant to either tilmicosin or tulathromycin.

1OTC

At least one
BRD
pathogen

BRD
Pathogen

with2

Table 2.6. Result of 5-fold cross-validation with the optimal Ct value obtained using ROC curves on the overall data
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Table 2.7. Optimal Cycle Threshold (Ct) value for lungs and nasal specimen
Lungs Specimen
Antimicrobials1
r

OTC (TET )
TIL
TUL
MACr

Optimal Cycle Threshold (Ct)

Kappa (κ)

35.66
33.12
32.64
33.12

0.61
0.61
0.63
0.62

Nasal Specimen
Optimal Cycle Threshold
(Ct)
33.27
-

Kappa (κ)
0.49
-

1OTC refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and
tulathromycin, two drugs tested for resistance that belong to the class of macrolides. MACr is used to indicate the samples that
resistant to either tilmicosin or tulathromycin.
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Table 3.1.. Distribution of the number of drugs administered to the cattle antemortem
Drug Count Category1
One Drug
More than One Drug
No Treatment
Missing
1

# Samples
93
48
265
10

% age
22.4%
11.5%
63.7%
2.4%

Drug Count Category was created based on the prior antibiotic treatment information. If one brand of drug or one drug class
(macrolide, tetracycline, amphenicol etc.) or some antibiotic treatment (but not specifically mentioning a drug name) was
provided then it was categorized as “One Drug”. If more than one brand of drug (resflor, advocin, draxxin etc.) or combination of
one brand of drug and drug class which was different than the brand of drug mentioned then it was categorized as “More than
one drug”. If no information regarding prior antibiotic treatment was available, then it was categorized as “No Treatment”. For
few samples, no information regarding the samples were provided, those were categorized as “Missing”.
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Table 3.2.. Distribution of the vaccination status administered to the cattle antemortem
Vaccination Status1
YES
NO
NOT KNOWN

# Samples
104
298
14

% age
25.0%
71.6%
3.4%

1 Vaccination status was created based on the prior vaccination/immunization information. If records relating to vaccines
administered were provided it was categorized as “YES”, if no vaccines were administered it was categorized as “NO”. For few
samples, vaccination information was not available they were categorized as “NOT KNOWN”.
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Table 3.3.. Average Ct and standard deviation for the gene targets before and after the
imputation with the highest quantification cycle
Gene
Target
tetH
erm42
msrE
mphE
1The

# Missing
observation (%1)
191 (46%)
325 (78%)
232 (56%)
257 (62%)

Before Imputation
Mean
SD
29.32
5.89
28.34
6.18
28.91
6.63
29.77
6.37

After Imputation2
Mean
SD
34.22
6.86
37.45
5.62
35.09
7.06
36.09
6.34

percentage for missing observations are calculated out of 416 samples.

2Missing

values were imputed with the highest quantification cycle 40
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Table 3.4.. Model performance and comparison of average accuracy in the training and
testing dataset for each antimicrobial

Antimicrobials
1

OTC

TIL

TUL

Model

Baseline
Model
Model 1
Model 2
Baseline
Model
Model 1
Model 2
Baseline
Model
Model 1
Model 2

Average
AIC2

Average
AUC3:
Training
Dataset

Average
H4:
Training
Dataset

Average
Accuracy
: Training
Dataset5

Average
Accuracy
: Test
Dataset5

Average
Accuracy
H:
Training
Dataset6

Average
Accuracy
H: Test
Dataset6

263.09
250.78
249.26

77.08%
79.89%
80.22%

46.58%
51.75%
53.62%

79.14%
82.20%
82.41%

80.54%
82.74%
82.78%

79.38%
78.56%
76.93%

80.05%
79.53%
77.19%

247.33
237.09
239.34

74.22%
75.89%
76.46%

43.09%
46.96%
47.68%

82.39%
83.89%
84.21%

81.96%
83.66%
83.74%

82.18%
81.34%
81.56%

81.69%
80.87%
81.26%

231.65
230.10
230.00

76.57%
77.13%
77.70%

45.32%
47.71%
49.33%

83.81%
84.59%
84.78%

83.77%
84.76%
84.92%

83.84%
83.21%
81.14%

83.79%
83.52%
80.77%

1OTC refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and
tulathromycin, two drugs tested for resistance that belong to the class of macrolides.
2AIC

– Akaike’s Information Criterion calculated for the training set (40 iterations)

3AUC
4H

– Area under the curve calculated for the training set (40 iterations)

– H measure calculated for the training set (40 iterations)

5Average

accuracy calculated for the 40 iterations based on the threshold 0.5

6Average

accuracy calculated for the 40 iterations based on the threshold calculated from the H measure
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Table 3.5.. Threshold estimated using the H measure along with a comparison of
minimum error rates’

Antimicrobials1
OTC

TIL

TUL

Model
Baseline Model
Model 1
Model 2
Baseline Model
Model 1
Model 2
Baseline Model
Model 1
Model 2

Average
Threshold - H
0.4402
0.4389
0.4150
0.5334
0.4295
0.4884
0.5175
0.4881
0.4684

Average
MER2
19.85%
17.30%
16.70%
16.44%
15.36%
14.86%
15.25%
14.69%
14.36%

Average ERAUC2
20.86%
17.80%
17.59%
18.31%
17.80%
17.59%
16.21%
16.48%
19.23%

1OTC

refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and
tulathromycin, two drugs tested for resistance that belong to the class of macrolides.
2Average
3Average

Minimum error rate is the minimum error rate among all the threshold calculated on the training set
error rate is the error rate based on the threshold ( = 0.5) calculated on the training set

Note: For AUC approach Average ER = 1 – Average Accuracy
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Table 3.6.. Optimal Cycle Threshold and the level of agreement

Antimicrobials1

OTC2

TIL3

TUL3

Model
Baseline
Model
Model 1
Model 2
Baseline
Model
Model 1
Model 2
Baseline
Model
Model 1
Model 2

Optimal
Ct: AUC4

Average
Kappa ( )5:
Training
Dataset

Average
Kappa ( ) 5:
Test
Dataset

Optimal
Ct: H6

Average
Kappa ( ) 5
H: Training
Dataset

Average
Kappa ( )
5
H: Test
Dataset

32.46
31.68
32.19

55.20%
61.45%
61.99%

58.64%
62.96%
63.14%

33.54
33.09
34.59

56.76%
54.64%
51.84%

58.47%
56.87%
52.55%

32.40
32.69
32.52

52.51%
56.34%
57.38%

53.11%
57.30%
57.64%

31.53
33.43
32.60

51.87%
51.83%
51.18%

52.23%
52.00%
51.42%

32.67
32.40
32.99

56.68%
58.41%
59.19%

55.65%
57.89%
58.48%

32.25
32.14
33.89

57.10%
54.80%
53.75%

56.05%
54.77%
52.43%

1OTC refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and
tulathromycin, two drugs tested for resistance that belong to the class of macrolides.
2The

optimal Ct evaluated for the tetracycline class of drug is for tetH

3The

optimal Ct evaluated for the macrolide class of drug is the average of erm42, msrE and mphE

4The

optimal Ct evaluated considering the probability threshold = 0.5

5

κ<0.2 implies poor level of agreement; 0.2<κ≤0.4 indicates fair level of agreement; 0.4<κ≤0.6 indicates moderate level of
agreement; 0.6<κ≤0.8 indicates good level of agreement, and κ>0.8 implies very good level of agreement.

6The

optimal Ct evaluated considering the probability threshold with minimum error rate
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Table 3.7.. Optimal Cycle Threshold for the best models
Antimicrobials1

Optimal Ct: AUC4

Optimal Ct: H5

OTC2

32.19

33.54

TIL3

32.52

31.53

TUL3

32.99

32.25

1OTC

refers to oxytetracycline, the drug tested belonging to the class of tetracycline, while TIL and TUL refer to tilmicosin and
tulathromycin, two drugs tested for resistance that belong to the class of macrolides.
2The

optimal Ct evaluated for the tetracycline class of drug is for tetH

3The

optimal Ct evaluated for the macrolide class of drug is the average of erm42, msrE and mphE

4The
5The

optimal Ct evaluated considering the probability threshold = 0.5

optimal Ct evaluated considering the probability threshold with minimum error rate
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6. List of figures

Figure 1.1 Two scenarios of optimal cutoff: Two scenarios where (A) the cutoff clearly
distinguishes between the diseased (red) and non-diseased (green) subjects, (B) cutoff unable to
distinguishes between the diseased (red) and non-diseased (green) subjects leading to the
misclassification area denoted by FP and FN (FP and FN are as described in Table 1.1). When
cutoff 1 is chosen, no FP, but has a high FN. When cutoff 2 is chosen, no FN but very high FP.
When cutoff 3 is chosen, both FN and FP exist, but in a more balanced small extent.

57

diagonal line denotes 1— = 0.5 indicating the model cannot discriminate between the
classes. The red curve denotes 1— 0 0.5 indicating the model can discriminate between
the classes.

Figure 1.2 Sample ROC curve: Sample ROC curve with shaded region as AUC. The black

58

Figure 1.3 Schematic illutstration of broth dilution and real-time PCR method:
Schematic illustration of results obtained from (A) broth dilution, (B) real-time PCR

59

Figure 2.1 Prevalence of BRD pathogens: Plot showing the estimate of prevalence along
with 95% confidence interval of at least one BRD pathogens among the lungs and nasal specimen.

60

Figure 2.2 Percentile distribution of gene targets: Percentile distribution of the three
target genes msrE, mphE, and erm42 conferring resistance to the macrolide group of drugs.

61

A

B

C

D

Figure 2.3.1 ROC Plots for the lungs specimen: ROC plots for the lungs specimen showing the
optimal Ct value based on the multiplex rtPCR assay equivalent to the gold standard (MIC test) for:
(A) Oxytetracycline, (B) Tilmicosin, (C) Tulathromycin and (D) Combined Macrolide group of drugs.

62

A

B

C

D

Figure 2.3.2 ROC plots for the nasal specimen: ROC plots for the nasal specimen
showing the optimal Ct value based on the multiplex rtPCR assay equivalent to the gold
standard (MIC test) for: (A) Oxytetracycline, (B) Tilmicosin, (C) Tulathromycin and (D)
Combined Macrolide group of drugs.

63

B

A

C

Figure 3.1.1 Average accuracy plots for Oxytetracycline: Average accuracy plots
comparing the three models for Oxytetracycline (OTC): (A) Baseline Model, (B) Model 1 and (C)
Model 2

64

A

B

C

Figure 3.1.2 Average accuracy plots for Tilmicosin: Average accuracy plots comparing
the three models for Tilmicosin (TIL): (A) Baseline Model, (B) Model 1 and (C) Model 2

65

A

B

C

Figure 3.1.3 Average accuracy plots for Tulathromycin: Average accuracy plots comparing
the three models for Tulathromycin (TUL): (A) Baseline Model, (B) Model 1 and (C) Model 2

66

A

B

C

D

Figure 4.1 Comparison of cost weight distribution used by AUC and H measure:
Comparison of the cost weight distribution between the Model 1 and Model 2 of Oxytetracycline
(OTC):- (A) cost weight distribution used by AUC for model 2 of OTC, (B) cost weight distribution
used by AUC for model 1 of OTC, (C) cost weight distribution used by H measure for model 2 of
OTC, (D) cost weight distribution used by H measure for model 1 of OTC
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